110 results about "Intestinal Disorder" patented technology

The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:

which relates to morphinan compounds useful as μ, δ, and/or κ receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

A pharmaceutical composition includes a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-S-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

The invention relates to compositions comprising one or more prebiotics (e.g., one or more dietary fibers) in combination with selenium compounds, flavonoids and/or flavonols, and phosphatides. The invention also relates to methods of regulating disorders, specifically disorders of the intestinal tract and related disorders, by administering a composition of the invention.

The invention relates to a preparation comprising 5-50% by weight of Isphagula Husk; 1-20% by weight of at least one amino acid; 20-80% by weight of at least one carbohydrate and electrolytes. The preparation is for use as a therapeutical agent, such as for use in treating a state of disorder in the intestinal system of monogastric animals, including humans. A state of disorder in the intestinal system is in particular all intestinal disorders in which the epithelial layer is damaged, mostly as a result of malabsorption diarrhoea, also associated with dehydration.

The present invention relates to a feed supplement which comprises a resin acid based composition comprising over 10% (w/w) resin acids for use in the prevention of growth of harmful bacteria in the animal digestive tract, in the prevention of intestinal disorders, in the modulation of microbial population of the animal digestive tract, in enhancing rumen fermentation, lowering rumen methane production and/or in binding toxins. The invention further relates to a use of the feed supplement and a feed composition comprising the feed supplement.

Food compositions whereby natto kinase, which is a component of natto, can be easily taken; and food compositions comprising a combination of a Japanese food material natto with a western food material fermented milk product, for each of which some people have a dislike, so as to achieve the hygienic advantages of both of these materials and expect specific hygienic effects. Namely, food compositions comprising a freeze-dried fermented milk product, natto kinase and carriers usable in foods; and functional foods containing these components which have effects of preventing thrombosis, improving blood fluidity, preventing platelet aggregation and ameliorating lipid metabolism. These food compositions enable not only to easily take the components of the fermented milk product and natto without showing the characteristic smell of natto but also to achieve hygienic effects including amelioration in intestinal disorders, immnopotentiation and antitumor activity caused by the fermented milk product as well as the prevention and treatment of thrombosis owing to the synergistic effect thereof with natto kinase.

The present invention relates to a tall oil fatty acid for use in the prevention of growth of harmful bacteria in the animal digestive tractand/or in the prevention of intestinal disorders. The invention further relates to a feed supplement and a feed composition comprising tall oil fatty acid.

An intestinal disease segmentation method of a significant edge feature extraction module guided network comprises the steps of: firstly, inputting a data set, extracting features through a backbone network Res2net, then extracting multi-scale context information through GCN modules with different kernel sizes, improving the division performance of object boundaries through a boundary refinement module, and further extracting the features; generating edge information by using the second-layer side edge output features, suppressing noise in the edge information by using the three fused high-layer semantic information, and performing significant edge supervision on the generated significant edge features by using a mask image generation edge image to form a final significant edge feature extraction module; and finally, jointly inputting the edge information generated in the significant edge feature extraction module and the side output information of each layer into the RAS module, and training the model to obtain training parameters, wherein the training parameters are used for testing to obtain a final result. According to the invention, the problems of inaccurate polyp segmentation and positioning and fuzzy boundary in gastrointestinal tracts are improved.

The invention relates to a preparation method of walnut and peanut milk. The preparation method particularly comprises the steps of preparing walnut juice, preparing peanut juice, processing fresh milk and preparing the walnut and peanut milk. In the invention, the prepared walnut and peanut milk diffuses fragrance all around, is good in taste, contains firm and uniform clots, is free from any bubbles, and is full of the fruity fragrance of walnut and peanut. The flavor of lactic acid is fragrant and pure, the fragrance is coordinated, and the taste is fine and smooth. The walnut and peanut milk contains a certain amount of lactobacillus, and achieves the additional function of relieving intestinal disorders. Moreover, the product has the rich fragrance of walnut and peanut as well as the unique flavor of fermented walnut and peanut, and is favourite among people.

Various types of synbiotic therapies are provided for the treatment of a variety of gastrointestinal and other disorders. The combination of prebiotics to probiotics is defined as a synbiotic therapy. The principal GI disorders associated with dysbiosis that can be treated from such a therapeutic intervention include but are not limited to: inflammatory bowel disease (IBD) (Crohn's disease and ulcerative colitis), irritable bowel syndrome (IBS), antibiotic-associated diarrheas such as recurrent Clostridium difficile infection, and possibly variants of Celiac disease. Other disorders that may also be ameliorated by the proposed synbiotic therapy include metabolic syndromes and central nervous system disorders. The disclosed methods and compositions were developed to improve upon currently available probiotics through consideration of the human intestinal microbiota, and its relationship to various intestinal metabolic and neuropsychiatric disorders. In one embodiment, the disclosed synbiotic compositions include prebiotics and a targeted delivery system, which altogether promote the survival, growth, and attachment of probiotic microbiota.

The present invention relates to a catalyst system. In particular the invention relates to a catalyst in the form of metal or an alloy that is encapsulated within a polymer shell or matrix. More specifically the invention is directed towards reactive catalytic metals that may be pyrophoric or otherwise reactive in air and/or susceptible to oxidation. In particular, the invention is concerned with catalysts based on nickel. Raney or sponge nickel is highly hazardous: a self-igniting solid; produces hazardous fumes when burning; causes irritation of the respiratory tract, nasal cavities; causes pulmonary fibrosis if inhaled; ingestion may lead to convulsions and intestinal disorders; causes eye and skin irritation; and chronic exposure may lead to pneumonitis and sensitization (''nickel itch''). The invention provides metal catalysts that avoid such problems and have a good shelf life and working life.

The present invention discloses probiotic and egg nutritional powder. The probiotic and egg nutritional powder comprises the following raw materials in parts by mass: 40-60 parts of egg powder, 20-40parts of inulin, 1-10 parts of citrus fibers, 1-10 parts of resistant dextrin, 0.5-15 parts of compound probiotic powder, 0.5-5 parts of stachyose, 0.5-5 parts of hydrolyzed egg yolk powder and 0.5-5parts of blueberry fruit powder. The present invention also discloses a preparation method of the probiotic and egg nutritional powder. The preparation method comprises the following steps of preparing egg powder, preparing compound probiotic powder and preparing probiotic and egg nutritional powder. The probiotic and egg nutritional powder is a solid drink having functions of preventing oxidation, nourishing intestinal flora, supplementing dietary fibers, moistening intestines and relaxing bowels, enhancing immunity, and improving sub-health, and can significantly alleviate increasingly striking sub-health problems of intestinal disorders, constipation, low immunity, etc. in long-term drinking.

An agent for relieving intestinal disorders which contain live cells of a strain belonging to Lactobacillus helveticus. This strain is preferably characterized by a resistance to a specific bile acid, adhesiveness to intestinal epithelial cells, etc. A method of controlling intestinal functions which involves the step of administering such a medicine to a subject with a need for the control of intestinal functions. When administered to humans or the like, these agents exert effects of elevating defecation frequency, etc., thereby efficaciously improving the intestinal environment.

Various types of synbiotic therapies are provided for the treatment of a variety of gastrointestinal and other disorders. The combination of prebiotics to probiotics is defined as a synbiotic therapy. The principal GI disorders associated with dysbiosis that can be treated from such a therapeutic intervention include but are not limited to: inflammatory bowel disease (IBD) (Crohn's disease and ulcerative colitis), irritable bowel syndrome (IBS), antibiotic-associated diarrheas such as recurrent Clostridium difficile infection, and possibly variants of Celiac disease. Other disorders that may also be ameliorated by the proposed synbiotic therapy include metabolic syndromes and central nervous system disorders. The disclosed methods and compositions were developed to improve upon currently available probiotics through consideration of the human intestinal microbiota, and its relationship to various intestinal metabolic and neuropsychiatric disorders. In one embodiment, the disclosed synbiotic compositions include prebiotics and a targeted delivery system, which altogether promote the survival, growth, and attachment of probiotic microbiota.